George Demetri, M.D., is a medical oncologist at the Dana-Farber Cancer Institute, where he also serves as the Director for the Center for Sarcoma and Bone Oncology, and an Associate Professor of Medicine at the Harvard Medical School. Dr. Demetri also chairs the Sarcoma Clinical Practice Guidelines Committee of the National Comprehensive Cancer Network and is the founder and editor of a wonderful web resource, Sarcoma.Net. He recently led the Phase II studies of Gleevec for GIST, as well as early studies of ET-743, the drug derived from sea squirts that has shown some success in treating some soft-tissue sarcomas. Dr. Demetri feels that his particular strength is new drug development based on rational scientific targets.
Burton Eisenberg, M.D., F.A.C.S., is a surgical oncologist at Dartmouth-Hitchcock Medical Center in Lebanon, NH. He serves as Deputy Director of the Norris Cotton Cancer Center and is a Professor of Surgery at the Geisel School of Medicine at Dartmouth. Doctor Eisenberg chaired the Sarcoma Working Group Committee of the Radiation Oncology Group (RTOG) until 2011. He has special interest in both clinical and translational research in soft tissue sarcomas. In addition, he is the author or co-author of a number of publications and book chapters related to the management of soft tissue sarcomas.
Charles Forscher, M.D., is a medical oncologist at Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute and Assistant Clinical Professor at the UCLA School of Medicine. His areas of expertise include chemotherapy for soft tissue and bone sarcomas as apart of a combined modality approach to sarcoma management. Dr. Forscher’s particular strength lies in utilizing nonadjuvant chemotherapy to gain a better understanding of the response of particular sarcomas to treatment. Dr. Forscher limits his practice to the study and treatment of sarcomas and has more than twenty years of experience in the field. His referral base is nationwide.
Linda Granowetter, M.D., is a pediatric oncologist at the Babies & Children’s Hospital of New York and Director of Pediatric Oncology at the Herbert Irving Child and Adolescent Cancer Center. Dr. Granowetter is also an Associate Professor of Clinical Pediatrics at Columbia University, College of Physicians and Surgeons. She is a member of the Columbia Presbyterian Cancer Center Sarcoma Group and the Children’s Oncology Group Ewing’s Sarcoma Subcommittee. Dr. Granowetter is a clinician who contributes to the treatment of sarcoma with her daily work and translates new biologic advances into appropriate and meaningful clinical trials.
Richard J. O’Donnell, M.D., is the Chief of the Orthopaedic Oncology Service as the UCSF Helen Diller Family Comprehenisive Cancer Center. He is a Professor of Clinical Orthopaedic Surgery at UCSF and Director of the UCSF Sarcoma Program. He has been a Sarcoma Alliance Medical Advisory Board member since 2002. He is also a member of the National Comprehensive Cancer Network’s Bone Cancer Panel, Sarcoma Cancer Panel and the Gastrointestinal Stromal Tumor Consensus Group. Doctor O’Donnell has done extensive research in the area of pediatric sarcomas and limb-salvage procedures. He is a member of the Connective Tissue Oncology Society, the Musculoskeletal Tumor Society, and the International Society on Limb Salvage. He is the Founder of the Orthopaedic Surgical Osseointegration Society.
To learn more visit his personal web page at:
Raphael Pollock, M.D., Ph.D., F.A.C.S., is a surgical oncologist and Head of the Division of Surgery at the University of Texas M.D. Anderson Cancer Center. He also serves as Professor and Chairman of the Department of Surgical Oncology and as Professor in the Department of Cancer Biology. Dr. Pollock is the Chairman of the National Sarcoma Patterns of Care Committee of the American College of Surgeons’ Commission on Cancer. He is also the Chairman of the Soft Tissue Sarcoma Task Force of the American Joint Committee on Cancer, Co-Chairman of the Sarcoma Committee of the National Cancer Center Coalition, and Chair of the Sarcoma Subcommittee of the Society of Surgical Oncology.
Matt van de Rijn